A Safety Study in Participants With Major Depressive Disorder
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of
LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin
reuptake inhibitor (SSRI) for up to approximately 1 year in participants with major
depressive disorder (MDD) who are partial responders to their SSRI treatment.